- Home
- BTE vs DVAX Comparison
BTE vs DVAX Comparison
Compare BTE & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- DVAX
- Stock Information
- Founded
- BTE 1993
- DVAX 1996
- Country
- BTE Canada
- DVAX United States
- Employees
- BTE N/A
- DVAX N/A
- Industry
- BTE Meat/Poultry/Fish
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- DVAX Health Care
- Exchange
- BTE Nasdaq
- DVAX Nasdaq
- Market Cap
- BTE 1.4B
- DVAX 1.3B
- IPO Year
- BTE N/A
- DVAX 2004
- Fundamental
- Price
- BTE $2.07
- DVAX $11.36
- Analyst Decision
- BTE Hold
- DVAX Buy
- Analyst Count
- BTE 1
- DVAX 4
- Target Price
- BTE $5.50
- DVAX $26.25
- AVG Volume (30 Days)
- BTE 34.1M
- DVAX 1.6M
- Earning Date
- BTE 07-31-2025
- DVAX 08-05-2025
- Dividend Yield
- BTE 3.12%
- DVAX N/A
- EPS Growth
- BTE N/A
- DVAX N/A
- EPS
- BTE 0.28
- DVAX N/A
- Revenue
- BTE $2,327,227,884.00
- DVAX $294,620,000.00
- Revenue This Year
- BTE $3.43
- DVAX $21.18
- Revenue Next Year
- BTE N/A
- DVAX $16.83
- P/E Ratio
- BTE $7.15
- DVAX N/A
- Revenue Growth
- BTE 10.55
- DVAX 24.76
- 52 Week Low
- BTE $1.36
- DVAX $9.22
- 52 Week High
- BTE $3.76
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- BTE 60.18
- DVAX 66.09
- Support Level
- BTE $1.90
- DVAX $10.38
- Resistance Level
- BTE $2.15
- DVAX $11.48
- Average True Range (ATR)
- BTE 0.10
- DVAX 0.30
- MACD
- BTE 0.02
- DVAX 0.08
- Stochastic Oscillator
- BTE 77.81
- DVAX 90.40
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.